Peak Expiratory Flow Rate for Emergency Department Management of Acute Asthma Exacerbation

Asthma Clinical Trial

Official title:

Peak Expiratory Flow Rate (PEFR) for Emergency Department Management of Acute Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03420651
• Other study ID #: 17-4459
• Status: Completed
• Phase: N/A
• Start date: January 19, 2018
• Est. completion date: November 30, 2022

Study information

• Verified date: September 2023
• Source: Hennepin Healthcare Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients presenting to the emergency department with acute asthma exacerbation will be assigned to peak-expiratory flow rate (PEFR) guided management and non-PEFR guided management.

Description:

It is common practice to use peak-expiratory flow rate (PEFR) as an indicator of severity in patients that present with acute asthma exacerbation. There is, however, little data supporting this practice.

A recent Canadian 20 site prospective observational cohort study of 805 ED patients with acute asthma exacerbation concluded PEFR was not useful in predicting need for hospitalization or relapse following discharge.

As this was a cohort observational study, the conclusions that can be drawn are limited by the lack of randomization and control; it is necessary to conduct a randomized controlled trial to quantify how much time is expended caring for these patients, and gather safety data.

This is important because no studies have quantified differences in resource utilization based on PEFR-guided management compared to non-PEFR-guided management. It is possible physicians following PEFR-guided management use comparatively more resources, such as nebulizer treatments and hospitalization, in order to treat low PEFR values in patients they would have otherwise discharged based on clinical judgement alone. If outcomes are not affected by non-PEFR-guided management, it may reduce resource utilization to avoid using PEFR-guided management.

The investigators seek to determine if PEFR-based management and non-PEFR-based management perform similarly in guiding ED management of acute asthma exacerbations. Specifically, they seek to determine if the proportion of patients with no or mild asthma symptoms at 150 minutes after enrollment arrival is similar in the two groups.

At 150 minutes, it is expected that approximately 80% of patients will have no or mild asthma symptoms in both groups. When comparing the proportion of patients between the two groups, a confidence interval less than 20% wide (10% on either side of the point estimate) is desired. Therefore, goal enrollment is 110 patients per group.

This study will only include patients who are discharged from the ED. Patients who are enrolled and then eventually admitted to the hospital will be tabulated but excluded from the analysis.

Statistical analysis will compare the difference in the proportion of patients who achieve the primary outcome between groups, with the associated 95% confidence interval. Secondary outcomes will be presented descriptively; depending on the final distribution of the data, the investigators will present the means or medians of the data with the associated difference in mean/median with the associated 95% confidence intervals

Recruitment information / eligibility

• Status: Completed
• Enrollment: 188
• Est. completion date: November 30, 2022
• Est. primary completion date: November 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 55 Years

Eligibility

Inclusion Criteria:

• Presumed diagnosis of asthma, requiring at least 2 nebulized albuterol treatments

• Presenting with acute asthma exacerbation defined as acute or subacute episodes of progressively worsening shortness of breath, cough, wheezing, and chest tightness, or some combination of these symptoms

• Start of enrollment process must occur within 15 minutes of being roomed in the ED

• Working phone number and willingness to be contacted at least 72 hours following encounter

Exclusion Criteria:

• Prisoner or in custody

• Pregnant

• Known diagnosis of COPD

• Co-morbid medical conditions that patient is seeking treatment for concurrently

• Non-English speaking

• Unable to provide informed consent

• In the resuscitation bay or on non-invasive positive pressure ventilation (NPPV)

Related Conditions & MeSH terms

• Asthma
• Emergencies

Intervention

Other:
• Peak Expiratory Flow Rate (PEFR)
PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.
• Standard Clinical Judgement
Providers will use physical exam and standard clinical judgement to guide management.

Locations

Country	Name	City	State
United States	Hennepin County Medical Center	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Hennepin Healthcare Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adequate control of asthma symptoms within 150 minutes	Proportion of patients reporting no or mild asthma symptoms at 150 minutes after enrollment	150 minutes
Secondary	Hospitalization during index encounter	Rate of hospitalization in both groups directly from initial ED encounter	12 hours
Secondary	ED Length of Stay	Time elapsed from when the patient is roomed until the time the MD places discharge order, by review of the Electronic Medical record by a blinded abstractor.	12 hours
Secondary	Number of nebulized treatments with short-acting beta antagonists (SABA)	This is defined as the number of nebulized treatments received in the emergency department during the encounter, by review of the Electronic Medical record by a blinded abstractor.	12 hours
Secondary	Relapse following discharge within 72 hours	Each patient will be assessed via chart review and telephone follow up to see if they visited an ED or urgent care for asthma symptoms during the 72 hour time frame. Rates of relapse will be compared between the two treatment arms.	72 hours